Yau, ThomasThomasYauKaseb, AhmedAhmedKasebANN-LII CHENGQin, ShukuiShukuiQinZhu, Andrew XAndrew XZhuChan, Stephen LStephen LChanMelkadze, TamarTamarMelkadzeSukeepaisarnjaroen, WattanaWattanaSukeepaisarnjaroenBreder, ValeryValeryBrederVerset, GontranGontranVersetGane, EdwardEdwardGaneBorbath, IvanIvanBorbathRangel, Jose David GomezJose David GomezRangelRyoo, Baek-YeolBaek-YeolRyooMakharadze, TamtaTamtaMakharadzeMerle, PhilippePhilippeMerleBenzaghou, FawziFawziBenzaghouMilwee, StevenStevenMilweeWang, ZhongZhongWangCurran, DominicDominicCurranKelley, Robin KateRobin KateKelleyRimassa, LorenzaLorenzaRimassa2024-03-292024-03-292024-0424681253https://scholars.lib.ntu.edu.tw/handle/123456789/641592The aim of the COSMIC-312 trial was to evaluate cabozantinib plus atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. In the initial analysis, cabozantinib plus atezolizumab significantly prolonged progression-free survival versus sorafenib. Here, we report the pre-planned final overall survival analysis and updated safety and efficacy results following longer follow-up.en[SDGs]SDG3journal article10.1016/S2468-1253(23)00454-5383648322-s2.0-85186665815https://api.elsevier.com/content/abstract/scopus_id/85186665815